Skip to content

A comparative study on the clinical efficacy and safety of different courses of etoricoxib in the treatment of knee osteoarthritis

A comparative study on the clinical efficacy and safety of different courses of etoricoxib in the treatment of knee osteoarthritis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500100140
Enrollment
Unknown
Registered
2025-04-03
Start date
2025-04-07
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Interventions

Long-course Treatment Group:None
Short-course Treatment Group:None
Medium-course Treatment Group:None

Sponsors

Chengdu Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) KOA patients who met the diagnostic criteria of Chinese Osteoarthritis Diagnosis and Treatment Guideline (2024 edition) and have been diagnosed; 2) Age >=50 years old; 3) The mean visual analogue scale (VAS) of KOA in the last 2 weeks was >=40 mm; 4) Understand and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1) women who plan to become pregnant while pregnant, breastfeeding, or within 3 months; 2) patients who are known to be allergic to this product or other oxib drugs and sulfonamides. 3) patients with asthma, urticaria, or allergic reactions induced by aspirin or other nsaids. 4) patients with hepatic and renal insufficiency. 5) patients with a history of gastrointestinal bleeding or perforation after use of nsaids. 6) patients with active GI ulcer/bleeding or previous recurrent GI ulcer/bleeding. 7) patients with severe heart failure, acute or severe coronary syndrome. 8) perioperative patients undergoing coronary artery bypass grafting (CABG). 9) patients taking medications that may interfere with the evaluation of efficacy (e.g., tricyclic antidepressants, anesthetics, hypnotics, sedatives). 10) other conditions considered by the investigator to preclude participation in this study.

Design outcomes

Primary

MeasureTime frame
PASS Score;

Secondary

MeasureTime frame
Differences before and after VAS scores of subjects in each group;The changes of WOMAC pain score, WOMAC function score and PGA score in each group;Effects of arthritis-related proteins and biochemical indices in subjects;The subjects' other laboratory indicators were different before and after comparison;The difference of shedding rate and concept of continuous treatment among all groups during treatment observation;

Countries

China

Contacts

Public ContactLiu Dong

Chengdu Second People's Hospital

898305762@qq.com+86 28 67830800

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026